Clinical Trial Update: A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial update reports results for patient preference regarding home administration of a subcutaneous fixed-dose combination of pertuzumab and trastuzum…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Inflammatory Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)
• Perjeta (pertuzumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Early Breast Cancer, Locally Advanced Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2026-01-12